Search

Your search keyword '"Weide, B"' showing total 258 results
Start Over Author "Weide, B"
258 results on '"Weide, B"'

1. Predictors of responses to immune checkpoint blockade in advanced melanoma.

Author

Jacquelot, N, Roberti, MP, Enot, DP, Rusakiewicz, S, Ternès, N, Jegou, S, Woods, DM, Sodré, AL, Hansen, M, Meirow, Y, Sade-Feldman, M, Burra, A, Kwek, SS, Flament, C, Messaoudene, M, Duong, CPM, Chen, L, Kwon, BS, Anderson, AC, Kuchroo, VK, Weide, B, Aubin, F, Borg, C, Dalle, S, Beatrix, O, Ayyoub, M, Balme, B, Tomasic, G, Di Giacomo, AM, Maio, M, Schadendorf, D, Melero, I, Dréno, B, Khammari, A, Dummer, R, Levesque, M, Koguchi, Y, Fong, L, Lotem, M, Baniyash, M, Schmidt, H, Svane, IM, Kroemer, G, Marabelle, A, Michiels, S, Cavalcanti, A, Smyth, MJ, Weber, JS, Eggermont, AM, and Zitvogel, L

Abstract

Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.

Published
2017

10. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (Nature Medicine, (2019), 25, 12, (1916-1927), 10.1038/s41591-019-0654-5)

Author

Liu, D. Schilling, B. Liu, D. Sucker, A. Livingstone, E. Jerby-Arnon, L. Zimmer, L. Gutzmer, R. Satzger, I. Loquai, C. Grabbe, S. Vokes, N. Margolis, C.A. Conway, J. He, M.X. Elmarakeby, H. Dietlein, F. Miao, D. Tracy, A. Gogas, H. Goldinger, S.M. Utikal, J. Blank, C.U. Rauschenberg, R. von Bubnoff, D. Krackhardt, A. Weide, B. Haferkamp, S. Kiecker, F. Izar, B. Garraway, L. Regev, A. Flaherty, K. Paschen, A. Van Allen, E.M. Schadendorf, D.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper. © 2020, The Author(s).

Published
2020

11. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma

Author

Livingstone, E., Zaremba, A., Horn, S., Ugurel, S., Casalini, B., Schlaak, M., Hassel, J. C., Herbst, R., Utikal, J. S., Weide, B., Gutzmer, R., Meier, F., Koelsche, C., Hadaschik, E., Sucker, A., Reis, H., Merkelbach-Bruse, S., Siewert, M., Sahm, F., von Deimling, A., Cosgarea, I., Zimmer, L., Schadendorf, D., Schilling, B., Griewank, K. G., Livingstone, E., Zaremba, A., Horn, S., Ugurel, S., Casalini, B., Schlaak, M., Hassel, J. C., Herbst, R., Utikal, J. S., Weide, B., Gutzmer, R., Meier, F., Koelsche, C., Hadaschik, E., Sucker, A., Reis, H., Merkelbach-Bruse, S., Siewert, M., Sahm, F., von Deimling, A., Cosgarea, I., Zimmer, L., Schadendorf, D., Schilling, B., and Griewank, K. G.

Abstract

Background GNAQ and GNA11 mutant nonuveal melanoma represent a poorly characterized rare subgroup of melanoma with a gene mutation profile similar to uveal melanoma. Objectives To characterize these tumours in terms of clinical behaviour and genetic characteristics. Methods Patients with nonuveal GNAQ/11 mutated melanoma were identified from the prospective multicentre tumour tissue registry ADOREG, Tissue Registry in Melanoma (TRIM) and additional cooperating skin cancer centres. Extensive data on patient, tumour and treatment characteristics were collected retrospectively. Targeted sequencing was used to determine tumour mutational burden. Immunohistochemistry staining was performed for programmed death-ligand 1 and BRCA1-associated protein (BAP)1. Existing whole-exome cutaneous and uveal melanoma data were analysed for mutation type and burden. Results We identified 18 patients with metastatic GNAQ/11 mutant nonuveal melanoma. Tumours had a lower tumour mutational burden and fewer ultraviolet signature mutations than cutaneous melanomas. In addition to GNAQ and GNA11 mutations (nine each), six splicing factor 3b subunit 1 (SF3B1), three eukaryotic translation initiation factor 1A X-linked (EIF1AX) and four BAP1 mutations were detected. In contrast to uveal melanoma, GNAQ/11 mutant nonuveal melanomas frequently metastasized lymphatically and concurrent EIF1AX, SF3B1 and BAP1 mutations showed no apparent association with patient prognosis. Objective response to immunotherapy was poor with only one partial response observed in 10 treated patients (10%). Conclusions Our findings suggest that GNAQ/11 mutant nonuveal melanomas are a subtype of melanoma that is both clinically and genetically distinct from cutaneous and uveal melanoma. As they respond poorly to available treatment regimens, novel effective therapeutic approaches for affected patients are urgently needed. What is already known about this topic? The rare occurrence of GNAQ/11 mutations in nonuveal melanom

Published
2020

15. Yes-Associated Protein 1 (YAP1) Promotes Melanoma Metastasis: P-071

Author

Meckbach, D., Menzel, M., Weide, B., Toussaint, C. N., Schilbach, K., Eigentler, T., Ikenberg, K., Busch, C., Quintanilla-Martinez, L., Kohlhofer, U., Göke, A., Göke, F., Handgretinger, R., Ottmann, C., Bastian, B., Garbe, C., Röcken, M., Perner, S., Kohlbacher, O., and Bauer, J.

Published
2013

18. The predictive and prognostic significance of cell‐free DNA concentration in melanoma

Author

Váraljai, R., primary, Elouali, S., additional, Lueong, S.S., additional, Wistuba‐Hamprecht, K., additional, Seremet, T., additional, Siveke, J.T., additional, Becker, J.C., additional, Sucker, A., additional, Paschen, A., additional, Horn, P.A., additional, Neyns, B., additional, Weide, B., additional, Schadendorf, D., additional, and Roesch, A., additional

Published
2020
Full Text
View/download PDF

19. GNAQandGNA 11mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma

Author

Livingstone, E., primary, Zaremba, A., additional, Horn, S., additional, Ugurel, S., additional, Casalini, B., additional, Schlaak, M., additional, Hassel, J.C., additional, Herbst, R., additional, Utikal, J.S., additional, Weide, B., additional, Gutzmer, R., additional, Meier, F., additional, Koelsche, C., additional, Hadaschik, E., additional, Sucker, A., additional, Reis, H., additional, Merkelbach‐Bruse, S., additional, Siewert, M., additional, Sahm, F., additional, Deimling, A., additional, Cosgarea, I., additional, Zimmer, L., additional, Schadendorf, D., additional, Schilling, B., additional, and Griewank, K.G., additional

Published
2020
Full Text
View/download PDF

23. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Author

Liu, D. Schilling, B. Liu, D. Sucker, A. Livingstone, E. Jerby-Amon, L. Zimmer, L. Gutzmer, R. Satzger, I. Loquai, C. Grabbe, S. Vokes, N. Margolis, C.A. Conway, J. He, M.X. Elmarakeby, H. Dietlein, F. Miao, D. Tracy, A. Gogas, H. Goldinger, S.M. Utikal, J. Blank, C.U. Rauschenberg, R. von Bubnoff, D. Krackhardt, A. Weide, B. Haferkamp, S. Kiecker, F. Izar, B. Garraway, L. Regev, A. Flaherty, K. Paschen, A. Van Allen, E.M. Schadendorf, D.

Abstract

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response. © 2019, The Author(s).

Published
2019

24. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Author

Schilling, B. Martens, A. Geukes Foppen, M.H. Gebhardt, C. Hassel, J.C. Rozeman, E.A. Gesierich, A. Gutzmer, R. Kähler, K.C. Livingstone, E. Diamantopoulos, P.T. Gogas, H. Madonna, G. Ascierto, P.A. Goldinger, S.M. Mangana, J. Garbe, C. Schadendorf, D. Blank, C. Weide, B.

Abstract

Background: Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong overall survival (OS) in patients with advanced B-Raf proto-oncogene (BRAF)-mutant melanoma. However, due to the lack of head-to-head trials, it remains unclear if one of these therapeutic approaches should be preferred in first-line therapy. Here, we present a retrospective analysis comparing anti-PD-1 monotherapy with BRAF/MAPK/ERK kinase (MEK) combined inhibition used as first-line agents in a real-world clinical setting. Patients and methods: Clinical data, routine blood counts and lactate dehydrogenase (LDH) levels of 301 patients with unresectable or metastatic melanoma harboring an activating mutation in BRAF (V600E/K) were included. Of these, 106 received anti-PD-1 antibodies, while 195 patients were treated with a selective BRAF inhibitor combined with an MEK inhibitor as palliative first-line therapy. Patients were sub-grouped according to previously described predictive and prognostic markers. Results: OS was significantly longer in patients receiving anti-PD-1 monotherapy compared to patients receiving combined MAPK inhibitors. Subsequent therapies were comparable among these groups. The difference in OS was less pronounced in patients with high LDH levels and visceral metastatic spread. Conclusion: First-line treatment with a PD-1 blocking antibody might be associated with longer OS than first-line inhibition of the MAPK pathway in patients with advanced melanoma harboring mutant BRAF. These hypothesis-generating data need to be confirmed or rejected in prospective, randomized trials. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2019

29. Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO

Author

Knispel, Sarah, Zimmer, Lisa, Gutzmer, R., Heinzerling, L., Weishaupt, C., Pföhler, C., Gesierich, A., Herbst, R., Kähler, K., Weide, B., Schlaak, M., Loquai, C., Utikal, J., Terheyden, P., Kaatz, M., Berking, C., Kreuter, A., Ulrich, J., Mohr, P., Dippel, E., Weichenthal, M., Livingstone, Elisabeth, Schadendorf, Dirk, and Ugurel, Selma

Subjects
Medizin
Published
2018

30. A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours

Author

Krauss, J., primary, Eigentler, T., additional, Schreiber, J., additional, Weishaupt, C., additional, Terheyden, P., additional, Heinzerling, L., additional, Mohr, P., additional, Weide, B., additional, Ochsenreither, S., additional, Gutzmer, R., additional, Becker, J.C., additional, Kiecker, F., additional, Funkner, F., additional, Heidenreich, R., additional, Kays, S.-K., additional, Klinkhardt, U., additional, Gnad-Vogt, U.S., additional, Scheel, B., additional, Schönborn-Kellenberger, O., additional, and Seibel, T., additional

Published
2019
Full Text
View/download PDF

31. The predictive and prognostic significance of cell‐free DNA concentration in melanoma.

Author

Váraljai, R., Elouali, S., Lueong, S.S., Wistuba‐Hamprecht, K., Seremet, T., Siveke, J.T., Becker, J.C., Sucker, A., Paschen, A., Horn, P.A., Neyns, B., Weide, B., Schadendorf, D., and Roesch, A.

Subjects
CIRCULATING tumor DNA, PROGNOSIS, DNA, SKIN cancer
Abstract

Background: Melanoma is the leading cause of skin cancer‐related deaths worldwide. While there have been significant improvements in the treatment of advanced melanoma in the past decade, biomarker development lagged behind. Objectives: The majority of liquid biopsy biomarkers rely on the analyses of oncogenic mutations; however, about 20% of melanoma patients are wild type. Therefore, validation of universal predictive and prognostic biomarkers is urgently needed. Methods: We analysed plasma samples in a discovery cohort (n = 20) and expansion cohort (n = 166) of metastatic melanoma patients and healthy donors (n = 116). Total plasma circulating cell‐free DNA (cfDNA) concentrations were measured on the Qubit® platform using assays for single‐(ss) and double (ds)‐stranded DNA, DNA spectrophotometry and RNase P qPCR. We explored the diagnostic, predictive and prognostic potential of cfDNA concentration by bio‐statistical methods and established a cfDNA threshold for risk stratification. Results: Our selected best method was Qubit® dsDNA assay which quantified higher plasma cfDNA concentrations in melanoma patients than in healthy controls (AUC 72%). Measurement of baseline cfDNA concentration revealed that high cfDNA was associated with presence of metastases and higher AJCC stage (P < 0.05). Furthermore, high baseline cfDNA was an indicator of shorter overall survival in patients with oncogenic mutations (HR 2.12, P = 0.0008), and in wild‐type patients (HR 5.55, P < 0.0001). Conclusions: We provide evidence that total cfDNA can be used as a biomarker for melanoma irrespective of the tumour genotype and can provide information on tumour load, risk of progression and risk of death. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesions

Author

Sucker, A. Zhao, F. Pieper, N. Heeke, C. Maltaner, R. Stadtler, N. Real, B. Bielefeld, N. Howe, S. Weide, B. Gutzmer, R. Utikal, J. Loquai, C. Gogas, H. Klein-Hitpass, L. Zeschnigk, M. Westendorf, A.M. Trilling, M. Horn, S. Schilling, B. Schadendorf, D. Griewank, K.G. Paschen, A.

Abstract

Melanoma treatment has been revolutionized by antibody-based immunotherapies. IFN 3 secretion by CD8 + T cells is critical for therapy efficacy having anti-proliferative and pro-Apoptotic effects on tumour cells. Our study demonstrates a genetic evolution of IFN 3 resistance in different melanoma patient models. Chromosomal alterations and subsequent inactivating mutations in genes of the IFN 3 signalling cascade, most often JAK1 or JAK2, protect melanoma cells from anti-Tumour IFN 3 activity. JAK1/2 mutants further evolve into T-cell-resistant HLA class I-negative lesions with genes involved in antigen presentation silenced and no longer inducible by IFN 3. Allelic JAK1/2 losses predisposing to IFN 3 resistance development are frequent in melanoma. Subclones harbouring inactivating mutations emerge under various immunotherapies but are also detectable in pre-Treatment biopsies. Our data demonstrate that JAK1/2 deficiency protects melanoma from anti-Tumour IFN 3 activity and results in T-cell-resistant HLA class I-negative lesions. Screening for mechanisms of IFN 3 resistance should be considered in therapeutic decision-making. © 2017 The Author(s).

Published
2017

33. Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients

Author

Zelba, H., Weide, B., Martens, A., Derhovanessian, E., Bailur, J. Kini, Kyzirakos, C., Pflugfelder, A., Eigentler, T.K., Giacomo, A.M. Di, Maio, M., Aarntzen, E.H.J.G., Vries, I.J.M. de, Sucker, A., Schadendorf, D., Buttner, P., Garbe, C., and Pawelec, G.

Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Abstract

Contains fulltext : 137631.pdf (Publisher’s version ) (Open Access) Purpose: We initially observed that the presence of circulating NY-ESO-1- and/or Melan-A-specific T-cells in stage IV melanoma patients was significantly associated with prolonged survival. Here we report on how the phenotypes and functions of these T-cells differentially impact survival in patients pre-selected for NY-ESO-1 and/or Melan-A reactivity. Experimental Design: We assayed functional antigen-reactive T-cells recognizing NY-ESO-1 and/or Melan-A after in vitro stimulation using overlapping peptide pools. After restimulation, we assayed six cytokines simultaneously by intracellular cytokine staining. This allowed us to analyze the functional antigen-response of both CD4+ and CD8+ T-cells at the single-cell level. Results: We observed that NY-ESO-1 stimulated mainly CD4+ T-cells, whereas Melan-A more often stimulated CD8+ T-cells. NY-ESO-1-reactivity was not associated with an additional impact on survival whether CD4+ or CD8+ T-cells or both were responding. In contrast, recognition of Melan-A by CD4+ T-cells was associated with reduced survival in our cohort of patients pre-selected for NY-ESO-1 and/or Melan-A reactivity i.e. in patients with exceptionally long survival. We further observed a negative effect on survival in patients with CD4+ T-cells producing IL-4 and IL-17 upon Melan-A stimulation. Their prognosis was comparable to patients without any Melan-A reactivity. Conclusions: The nature and prognostic impact of specific T cell responses is different according to targeted antigen. Independent from phenotype and functional aspects, NY-ESO-1-reactivity is associated with good prognosis. For Melan-A, antigen-specific CD8+, but not CD4+ responses are associated with prolonged survival.

Published
2014

36. Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients

Author

Cosgarea, I, Zimmer, L., Weide, B., Gutzmer, R., Heinzerling, L., Weishaupt, C., Pfoehler, C., Gesierich, A., Herbst, R., Kaehler, K., Schlaak, M., Loquai, C., Utikal, J., Kaatz, M., Berking, C., Kreuter, A., Ulrich, J., Mohr, P., Dippel, E., Livingstone, E., Weichenthal, M., Schadendorf, D., Ugurel, S., Cosgarea, I, Zimmer, L., Weide, B., Gutzmer, R., Heinzerling, L., Weishaupt, C., Pfoehler, C., Gesierich, A., Herbst, R., Kaehler, K., Schlaak, M., Loquai, C., Utikal, J., Kaatz, M., Berking, C., Kreuter, A., Ulrich, J., Mohr, P., Dippel, E., Livingstone, E., Weichenthal, M., Schadendorf, D., and Ugurel, S.

Published
2017

39. CD74 expression in tumor cells is a positive prognostic marker for brain metastases patients

Author

Zeiner, PS, Bernatz, S, Ronellenfitsch, MW, Zinke, J, Thorsen, F, Plate, KH, Beschorner, R, Weide, B, Wischhusen, J, Mittelbronn, M, and Harter, PN

Subjects
ddc: 610, otorhinolaryngologic diseases, 610 Medical sciences, Medicine
Abstract

The macrophage migration inhibitory factor (MIF) receptor CD74 (also known as invariant chain) is upregulated in numerous peripheral neoplasms and has also been described as one of the most overexpressed molecules in primary brain tumors. While under certain circumstances MIF-CD74 interactions, lead[for full text, please go to the a.m. URL], 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

Published
2015
Full Text
View/download PDF

40. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma

Author

Wagner, N B, Weide, B, Reith, M, Tarnanidis, K, Kehrel, C, Lichtenberger, R, Pflugfelder, A, Herpel, E, Eubel, J, Ikenberg, K, Busch, C, Holland-Letz, T, Naeher, H, Garbe, C, Umansky, V, Enk, A, Utikal, J, Gebhardt, C, University of Zurich, and Gebhardt, C

Subjects
Cancer Research, Oncology, 10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published
2015

41. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: A randomized, multicentre, placebo-controlled double-blind phase II trial

Author

Pflugfelder, A. Andonov, E. Weide, B. Dirschka, T. Schempp, C. Stockfleth, E. Stratigos, A. Krüger-Krasagakis, S. Bauer, J. Garbe, C. Eigentler, T.K.

Abstract

Background Betulinic acid and other triterpenes have shown strong antitumour activity in vitro and in vivo. A triterpene extract of birch bark formed the base of Oleogel-S10 and allowed topical application. Two previous trials have shown efficacy and tolerability in the treatment of actinic keratoses (AKs) with betulin-based Oleogel-S10. Objectives To confirm the efficacy and tolerability/safety of Oleogel-S10 in the treatment of AKs in a multicentre placebo-controlled study. Methods Patients (n = 165) were treated topically for 3 months in a four-arm parallel study design, randomly allocated to A (n = 53) Oleogel-S10 once daily, B (n = 51) Oleogel-S10 twice daily, or C (n = 25) or D (n = 28) placebo (petroleum jelly) once or twice daily, respectively. Clinical efficacy in this double-blind study was assessed by the investigators. Final and baseline biopsies were evaluated by central histopathology. Results Complete clearance of the target lesions was seen in 4% of patients in group A and 7% in group B, but not in the placebo groups. A clearance rate of > 75% was seen for 15% and 18% of patients in groups A and B, respectively, and for 13% in the placebo groups. These differences were not statistically significant. Histopathologically, 43·9% of patients showed a downgrading or clearance of the marker AK with no significant differences between the groups. Treatment with Oleogel-S10 was well tolerated. The tolerability as assessed by the investigator was mostly 'very good' (78·8%), followed by 'good' (18·2%) and only 1·2% assessed it as 'intolerable'. Patient-assessed tolerability was graded mostly 'very good' (56·4%) or 'good' (34·5%). Conclusions Treatment with Oleogel-S10 was well tolerated during a treatment period of 3 months, yet was no better than placebo in terms of efficacy in the treatment of AKs. What's already known about this topic? Previous single open-label trials have shown activity for Oleogel-S10 in actinic keratoses, with a clearance of > 75% of the lesions in 79% and 86% of patients. What does this study add? In this multicentre randomized double-blind trial Oleogel-S10 was highly tolerable but could not demonstrate superiority over placebo treatment. © 2014 British Association of Dermatologists.

Published
2015

42. Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

Author

Nanda, VGY, Peng, W, Hwu, P, Davies, MA, Ciliberto, G, Fattore, L, Malpicci, D, Aurisicchio, L, Ascierto, PA, Croce, CM, Mancini, R, Spranger, S, Gajewski, TF, Wang, Y, Ferrone, S, Vanpouille-Box, C, Wennerberg, E, Pilones, KA, Formenti, SC, Demaria, S, Tang, H, Fu, Y-X, Dummer, R, Puzanov, I, Tarhini, A, Chauvin, J-M, Pagliano, O, Fourcade, J, Sun, Z, Wang, H, Sanders, C, Kirkwood, JM, Chen, T-HT, Maurer, M, Korman, AJ, Zarour, HM, Stroncek, DF, Huber, V, Rivoltini, L, Thurin, M, Rau, T, Lugli, A, Pagès, F, Camarero, J, Sancho, A, Jommi, C, de Coaña, YP, Wolodarski, M, Yoshimoto, Y, Gentilcore, G, Poschke, I, Masucci, GV, Hansson, J, Kiessling, R, Scognamiglio, G, Sabbatino, F, Marino, FZ, Anniciello, AM, Cantile, M, Cerrone, M, Scala, S, D’alterio, C, Ianaro, A, Cirin, G, Liguori, G, Bott, G, Chapman, PB, Robert, C, Larkin, J, Haanen, JB, Ribas, A, Hogg, D, Hamid, O, Testori, A, Lorigan, P, Sosman, JA, Flaherty, KT, Yue, H, Coleman, S, Caro, I, Hauschild, A, McArthur, GA, Sznol, M, Callahan, MK, Kluger, H, Postow, MA, Gordan, R, Segal, NH, Rizvi, NA, Lesokhin, A, Atkins, MB, Burke, MM, Ralabate, A, Rivera, A, Kronenberg, SA, Agunwamba, B, Ruisi, M, Horak, C, Jiang, J, Wolchok, J, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stoyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Chang, I, Koralek, DO, Rooney, I, Yan, Y, Dréno, B, Sullivan, R, Patel, M, Hodi, S, Amaria, R, Boasberg, P, Wallin, J, He, X, Cha, E, Richie, N, Ballinger, M, Smith, DC, Bauer, TM, Wasser, JS, Luke, JJ, Balmanoukian, AS, Kaufman, DR, Zhao, Y, Maleski, J, Leopold, L, Gangadhar, TC, Long, GV, Michielin, O, VanderWalde, A, Andtbacka, RHI, Cebon, J, Fernandez, E, Malvehy, J, Olszanski, AJ, Gause, C, Chen, L, Chou, J, Stephen Hodi, F, Brady, B, Mortier, L, Hassel, JC, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Lebbé, C, Ny, L, Chacon, M, Queirolo, P, Loquai, C, Cheema, P, Berrocal, A, Eizmendi, KM, Bar-Sela, G, Hardy, H, Weber, JS, Grob, J-J, Marquez-Rodas, I, Schmidt, H, Briscoe, K, Baurain, J-F, Wolchok, JD, Pinto, R, De Summa, S, Garrisi, VM, Strippoli, S, Azzariti, A, Guida, G, Guida, M, Tommasi, S, Jacquelot, N, Enot, D, Flament, C, Pitt, JM, Vimond, N, Blattner, C, Yamazaki, T, Roberti, M-P, Vetizou, M, Daillere, R, Poirier-Colame, V, la Semeraro, M, Caignard, A, Slingluff, CL, Sallusto, F, Rusakiewicz, S, Weide, B, Marabelle, A, Kohrt, H, Dalle, S, Cavalcanti, A, Kroemer, G, Di Giacomo, AM, Wong, P, Yuan, J, Umansky, V, Eggermont, A, Zitvogel, L, Anna, P, Marco, T, Stefania, S, Francesco, M, Mariaelena, C, Gabriele, M, Antonio, AP, Franco, S, Roberti, MP, Enot, DP, Semeraro, M, Jégou, S, Flores, C, Kwon, BS, Anderson, AC, Borg, C, Aubin, F, Ayyoub, M, De Presbiteris, AL, Cordaro, FG, Camerlingo, R, Fratangelo, F, Mozzillo, N, Pirozzi, G, Patriarca, EJ, Caputo, E, Motti, ML, Falcon, R, Miceli, R, Capone, M, Madonna, G, Mallardo, D, Carrier, MV, Panza, E, De Cicco, P, Armogida, C, Ercolano, G, Botti, G, Cirino, G, Sandru, A, Blank, M, Balatoni, T, Olasz, J, Farkas, E, Szollar, A, Savolt, A, Godeny, M, Csuka, O, Horvath, S, Eles, K, Shoenfeld, Y, Kasler, M, Costantini, S, Capone, F, Moradi, F, Berglund, P, Leandersson, K, Linnskog, R, Andersson, T, Prasad, CP, Nigro, CL, Lattanzio, L, Proby, C, Syed, N, Occelli, M, Cauchi, C, Merlano, M, Harwood, C, Thompson, A, Crook, T, Bifulco, K, Ingangi, V, Minopoli, M, Ragone, C, Pessi, A, Mannavola, F, D’Oronzo, S, Felici, C, Tucci, M, Doronzo, A, Silvestris, F, Ferretta, A, Guida, S, Maida, I, Cocco, T, Passarelli, A, Quaresmini, D, Franzese, O, Palermo, B, Di Donna, C, Sperduti, I, Foddai, M, Stabile, H, Gismondi, A, Santoni, A, Nisticò, P, Sponghini, AP, Platini, F, Marra, E, Rondonotti, D, Alabiso, O, Fierro, MT, Savoia, P, Stratica, F, Quaglino, P, Di Monta, G, Corrado, C, Di Marzo, M, Ugo, M, Di Cecilia, ML, Nicola, M, Fusciello, C, Marra, A, Guarrasi, R, Baldi, C, Russo, R, Di Giulio, G, Faiola, V, Zeppa, P, Pepe, S, Gambale, E, Carella, C, Di Paolo, A, De Tursi, M, Marra, L, De Murtas, F, Sorrentino, V, Voinea, S, Panaitescu, E, Bolovan, M, Stanciu, A, Cinca, S, Botti, C, Aquino, G, Anniciello, A, Fortes, C, Mastroeni, S, Caggiati, A, Passarelli, F, Zappalà, A, Capuano, M, Bono, R, Nudo, M, Marino, C, Michelozzi, P, De Biasio, V, Battarra, VC, Formenti, S, Ascierto, ML, McMiller, TL, Berger, AE, Danilova, L, Anders, RA, Netto, GJ, Xu, H, Pritchard, TS, Fan, J, Cheadle, C, Cope, L, Drake, CG, Pardoll, DM, Taube, JM, Topalian, SL, Gnjatic, S, Nataraj, S, Imai, N, Rahman, A, Jungbluth, AA, Pan, L, Venhaus, R, Park, A, Lehmann, FF, Lendvai, N, Cohen, AD, Cho, HJ, Daniel, S, Hirsh, V, Nanda, VGY, Peng, W, Hwu, P, Davies, MA, Ciliberto, G, Fattore, L, Malpicci, D, Aurisicchio, L, Ascierto, PA, Croce, CM, Mancini, R, Spranger, S, Gajewski, TF, Wang, Y, Ferrone, S, Vanpouille-Box, C, Wennerberg, E, Pilones, KA, Formenti, SC, Demaria, S, Tang, H, Fu, Y-X, Dummer, R, Puzanov, I, Tarhini, A, Chauvin, J-M, Pagliano, O, Fourcade, J, Sun, Z, Wang, H, Sanders, C, Kirkwood, JM, Chen, T-HT, Maurer, M, Korman, AJ, Zarour, HM, Stroncek, DF, Huber, V, Rivoltini, L, Thurin, M, Rau, T, Lugli, A, Pagès, F, Camarero, J, Sancho, A, Jommi, C, de Coaña, YP, Wolodarski, M, Yoshimoto, Y, Gentilcore, G, Poschke, I, Masucci, GV, Hansson, J, Kiessling, R, Scognamiglio, G, Sabbatino, F, Marino, FZ, Anniciello, AM, Cantile, M, Cerrone, M, Scala, S, D’alterio, C, Ianaro, A, Cirin, G, Liguori, G, Bott, G, Chapman, PB, Robert, C, Larkin, J, Haanen, JB, Ribas, A, Hogg, D, Hamid, O, Testori, A, Lorigan, P, Sosman, JA, Flaherty, KT, Yue, H, Coleman, S, Caro, I, Hauschild, A, McArthur, GA, Sznol, M, Callahan, MK, Kluger, H, Postow, MA, Gordan, R, Segal, NH, Rizvi, NA, Lesokhin, A, Atkins, MB, Burke, MM, Ralabate, A, Rivera, A, Kronenberg, SA, Agunwamba, B, Ruisi, M, Horak, C, Jiang, J, Wolchok, J, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stoyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Chang, I, Koralek, DO, Rooney, I, Yan, Y, Dréno, B, Sullivan, R, Patel, M, Hodi, S, Amaria, R, Boasberg, P, Wallin, J, He, X, Cha, E, Richie, N, Ballinger, M, Smith, DC, Bauer, TM, Wasser, JS, Luke, JJ, Balmanoukian, AS, Kaufman, DR, Zhao, Y, Maleski, J, Leopold, L, Gangadhar, TC, Long, GV, Michielin, O, VanderWalde, A, Andtbacka, RHI, Cebon, J, Fernandez, E, Malvehy, J, Olszanski, AJ, Gause, C, Chen, L, Chou, J, Stephen Hodi, F, Brady, B, Mortier, L, Hassel, JC, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Lebbé, C, Ny, L, Chacon, M, Queirolo, P, Loquai, C, Cheema, P, Berrocal, A, Eizmendi, KM, Bar-Sela, G, Hardy, H, Weber, JS, Grob, J-J, Marquez-Rodas, I, Schmidt, H, Briscoe, K, Baurain, J-F, Wolchok, JD, Pinto, R, De Summa, S, Garrisi, VM, Strippoli, S, Azzariti, A, Guida, G, Guida, M, Tommasi, S, Jacquelot, N, Enot, D, Flament, C, Pitt, JM, Vimond, N, Blattner, C, Yamazaki, T, Roberti, M-P, Vetizou, M, Daillere, R, Poirier-Colame, V, la Semeraro, M, Caignard, A, Slingluff, CL, Sallusto, F, Rusakiewicz, S, Weide, B, Marabelle, A, Kohrt, H, Dalle, S, Cavalcanti, A, Kroemer, G, Di Giacomo, AM, Wong, P, Yuan, J, Umansky, V, Eggermont, A, Zitvogel, L, Anna, P, Marco, T, Stefania, S, Francesco, M, Mariaelena, C, Gabriele, M, Antonio, AP, Franco, S, Roberti, MP, Enot, DP, Semeraro, M, Jégou, S, Flores, C, Kwon, BS, Anderson, AC, Borg, C, Aubin, F, Ayyoub, M, De Presbiteris, AL, Cordaro, FG, Camerlingo, R, Fratangelo, F, Mozzillo, N, Pirozzi, G, Patriarca, EJ, Caputo, E, Motti, ML, Falcon, R, Miceli, R, Capone, M, Madonna, G, Mallardo, D, Carrier, MV, Panza, E, De Cicco, P, Armogida, C, Ercolano, G, Botti, G, Cirino, G, Sandru, A, Blank, M, Balatoni, T, Olasz, J, Farkas, E, Szollar, A, Savolt, A, Godeny, M, Csuka, O, Horvath, S, Eles, K, Shoenfeld, Y, Kasler, M, Costantini, S, Capone, F, Moradi, F, Berglund, P, Leandersson, K, Linnskog, R, Andersson, T, Prasad, CP, Nigro, CL, Lattanzio, L, Proby, C, Syed, N, Occelli, M, Cauchi, C, Merlano, M, Harwood, C, Thompson, A, Crook, T, Bifulco, K, Ingangi, V, Minopoli, M, Ragone, C, Pessi, A, Mannavola, F, D’Oronzo, S, Felici, C, Tucci, M, Doronzo, A, Silvestris, F, Ferretta, A, Guida, S, Maida, I, Cocco, T, Passarelli, A, Quaresmini, D, Franzese, O, Palermo, B, Di Donna, C, Sperduti, I, Foddai, M, Stabile, H, Gismondi, A, Santoni, A, Nisticò, P, Sponghini, AP, Platini, F, Marra, E, Rondonotti, D, Alabiso, O, Fierro, MT, Savoia, P, Stratica, F, Quaglino, P, Di Monta, G, Corrado, C, Di Marzo, M, Ugo, M, Di Cecilia, ML, Nicola, M, Fusciello, C, Marra, A, Guarrasi, R, Baldi, C, Russo, R, Di Giulio, G, Faiola, V, Zeppa, P, Pepe, S, Gambale, E, Carella, C, Di Paolo, A, De Tursi, M, Marra, L, De Murtas, F, Sorrentino, V, Voinea, S, Panaitescu, E, Bolovan, M, Stanciu, A, Cinca, S, Botti, C, Aquino, G, Anniciello, A, Fortes, C, Mastroeni, S, Caggiati, A, Passarelli, F, Zappalà, A, Capuano, M, Bono, R, Nudo, M, Marino, C, Michelozzi, P, De Biasio, V, Battarra, VC, Formenti, S, Ascierto, ML, McMiller, TL, Berger, AE, Danilova, L, Anders, RA, Netto, GJ, Xu, H, Pritchard, TS, Fan, J, Cheadle, C, Cope, L, Drake, CG, Pardoll, DM, Taube, JM, Topalian, SL, Gnjatic, S, Nataraj, S, Imai, N, Rahman, A, Jungbluth, AA, Pan, L, Venhaus, R, Park, A, Lehmann, FF, Lendvai, N, Cohen, AD, Cho, HJ, Daniel, S, and Hirsh, V

Abstract

MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunosc

Published
2016

43. 509TiP - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours

Author

Krauss, J., Eigentler, T., Schreiber, J., Weishaupt, C., Terheyden, P., Heinzerling, L., Mohr, P., Weide, B., Ochsenreither, S., Gutzmer, R., Becker, J.C., Kiecker, F., Funkner, F., Heidenreich, R., Kays, S.-K., Klinkhardt, U., Gnad-Vogt, U.S., Scheel, B., Schönborn-Kellenberger, O., and Seibel, T.

Published
2019
Full Text
View/download PDF

44. Recent observations of the introduced Fenestrulina delicia Winston, Hayward & Craig, 2000 (Bryozoa) in Western Europe

Author

De Blauwe, H., Kind, B., Kuhlenkamp, R., Cuperus, J., van der Weide, B., and Kerckhof, F.

Subjects
Bryozoa
Abstract

We detail the discovery of recently established immigrant populations and beached material of the encrusting bryozoan Fenestrulina delicia from the Atlantic coasts of Europe. This species of unknown origin is highly invasive and, in contrast to most other introduced bryozoans spreads along offshore natural and artificial hard substrates, rather than hopping from one marina to another. Part of the material, collected in situ, was found on empty shells at locations well known for their aquaculture of oysters and mussels. This suggests that the import of shellfish could be the vector of primary introduction. Beached material suggests that floating plastic debris might be a vector of transport for secondary introduction. The base of offshore wind turbines forms a supplementary substrate in the sandy southern North Sea and probably provides stepping stones for this exotic species.

Published
2014

46. Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma

Author

Schilling, B, Sondermann, W, Zhao, F, Griewank, K G, Livingstone, E, Sucker, A, Zelba, H, Weide, B, Trefzer, U, Wilhelm, T, Loquai, C, Berking, C, Hassel, J, Kähler, K C, Utikal, J, Al Ghazal, P, Gutzmer, R, Goldinger, S M, Zimmer, L, Paschen, A, Hillen, U, Schadendorf, D, Dermatologic Cooperative Oncology Group, Schilling, B, Sondermann, W, Zhao, F, Griewank, K G, Livingstone, E, Sucker, A, Zelba, H, Weide, B, Trefzer, U, Wilhelm, T, Loquai, C, Berking, C, Hassel, J, Kähler, K C, Utikal, J, Al Ghazal, P, Gutzmer, R, Goldinger, S M, Zimmer, L, Paschen, A, Hillen, U, Schadendorf, D, and Dermatologic Cooperative Oncology Group

Abstract

In this study, we demonstrate that vemurafenib but not dabrafenib reduces peripheral lymphocyte counts in melanoma patients while both agents show similar clinical efficacy. Within the lymphocyte compartment, vemurafenib selectively decreases circulating CD4+ T cells and changes their phenotype and function. This indicates that selective BRAFi need to be assessed individually for immunomodulatory effects, especially, when planning combinations with immunotherapies

Published
2014

47. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.

Author

Weide, B., Zelba, H., Derhovanessian, E., Pflugfelder, A., Eigentler, T.K., Giacomo, A.M. Di, Maio, M., Aarntzen, E.H.J.G., Vries, I.J.M. de, Sucker, A., Schadendorf, D., Buttner, P., Garbe, C., Pawelec, G., Weide, B., Zelba, H., Derhovanessian, E., Pflugfelder, A., Eigentler, T.K., Giacomo, A.M. Di, Maio, M., Aarntzen, E.H.J.G., Vries, I.J.M. de, Sucker, A., Schadendorf, D., Buttner, P., Garbe, C., and Pawelec, G.

Abstract

Item does not contain fulltext, PURPOSE: To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis. PATIENTS AND METHODS: We examined 84 patients with follow-up after analysis (cohort A), 18 long-term survivors with an extraordinarily favorable course of disease before analysis (> 24 months survival after first occurrence of distant metastases; cohort B), and 14 healthy controls. Circulating antigen-reactive T cells were characterized by intracellular cytokine staining after in vitro stimulation. RESULTS: In cohort A patients, the presence of T cells responding to peptides from NY-ESO-1, Melan-A, or MAGE-3 and the M category according to the American Joint Committee on Cancer classification were significantly associated with survival. T cells responding to NY-ESO-1 and Melan-A (hazard ratios, 0.29 and 0.18, respectively) remained independent prognostic factors in Cox regression analysis and were superior to the M category in predicting outcome. Median survival of patients possessing T cells responding to NY-ESO-1, Melan-A, or both was 21 months, compared with 6 months for all others. NY-ESO-1-responsive T cells were detected in 70% of cohort A patients surviving > 18 months and in 50% of cohort B patients. Melan-A responses were found in 42% and 47% of patients in cohorts A and B, respectively. In contrast, the proportion was only 22% for NY-ESO-1 and 23% for Melan-A in those who died within 6 months. CONCLUSION: The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. Our findings support the therapeutic relevance of Melan-A and NY-ESO-1 as targets for immunotherapy.

Published
2012

49. A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma.

Author

Eigentler, T. K., primary, Weide, B., additional, Spitaleri, G., additional, De Braud, F. G., additional, Romanini, A., additional, Gonzales-Inglesias, R., additional, Tasciotti, A., additional, Giovannoni, L., additional, Schwager, K., additional, Lovato, V., additional, Kaspar, M., additional, Trachsel, E., additional, Neri, D., additional, Menssen, H. D., additional, and Garbe, C., additional

Published
2011
Full Text
View/download PDF

50. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group

Author

Pflugfelder, A., primary, Welter, A.-K., additional, Leiter, U., additional, Weide, B., additional, Held, L., additional, Eigentler, T.K., additional, Dirschka, T., additional, Stockfleth, E., additional, Nashan, D., additional, and Garbe, C., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results